1 minute reading time (44 words)

ICER Releases Evidence Report on Treatments for Sickle Cell Disease

The Institute for Clinical and Economic Review (ICER) today released an Evidence Report assessing the comparative clinical effectiveness and value of treatments for sickle cell disease, including crizanlizumab (Adakveo®, Novartis), voxelotor (Oxbryta™, Global Blood Therapeutics), and L-glutamine (Endari®, Emmaus Life Sciences). Full story

Related Posts

The AAPM Annual Meeting offers education and networking opportunities for all members of the pain care team.

Learn More